Portfolio articles – Sound Bioventures

All Fund articles Fund PR Portfolio articles Portfolio PR

Breye Therapeutics raises €67.5 million in over-subscribed Series A financing

2026.09.292026.09.29 / Co-led by new investor Mission BioCapital and existing investor Novo Holdings, with additional investment from existing syndicate member Sound Bioventures, and new investors the Ljungström family of ...

Simon Mølgaard Named Rising Star in Danish Biotech

2026.06.292026.06.29 / We are proud to congratulate Simon Mølgaard, CEO of our portfolio company Teitur Trophics, on being awarded the Rising Star in Danish Biotech at the Biotech Spring Gala — with the recognition display ...

Listen in to Professor Lars Lund, founder at AnaCardio, discussing the findings from GOAL-HF1, the first study using our oral ghrelin agonist, AC01, in patients with HFrEF

2026.06.082026.06.29 / https://soundbioventures.com/wp-content/uploads/2026/06/HFA-2026_-AC01-in-HFrEF-—-Safety-and-Efficacy-from-GOAL-HF1-_-AnaCardio-1.html ...

Read about Artax Biopharma and their journey developing a revolutionary therapy for autoimmune diseases that makes a meaningful difference in patients lives.

Transitioning a novel mechanism of action into clinical development

2026.06.082026.06.08 / Artax Biopharma is turning breakthrough science on T-cell responses into first-in-class therapies for autoimmune diseases. For the company’s CEO, Dr. Rob Armstrong, it’s a level of transformation tha ...

Natalie Mount - Cytospire Therapeutics

Turning a unique immunotherapy approach into better cancer treatments

2026.06.082026.06.08 / Based in the United Kingdom, Cytospire Therapeutics is developing antibody-based immune cell engagers with potentially improved response in cancer patients. It’s the kind of paradigm-shifting medicin ...

Maximizing value when developing oncolytic viral therapy

2025.04.012025.04.30 / As the new CEO for Theolytics, David Apelian aims to take full advantage of the first clinical studies for the company’s lead product. The UK-based biotech has a whole potential platform for creating ...

Applying the best of both science and business to treat heart failure

2025.01.312025.04.30 / AnaCardio is focused on bringing treatment for one of today’s largest unmet medical needs to market. According to CEO Patrik Strömberg, the Swedish biopharmaceutical company is leveraging strong scie ...

Navigating the journey of orphan drug development

2024.06.282024.06.28 / A new drug rarely takes a direct path from idea to patient, especially a first-in-class therapy. For NephroDI Therapeutics, developing a novel approach addressing the critical unmet medical need of a ...

Johan Kördel Ph.D., Managing Partner - Sound Bioventures

Sound Bioventures: Putting Scandinavian Biotechs on the Global Stage

2024.06.042024.09.09 / In this keynote presentation from the BioStock Global Forum, Sound Bioventures' Managing Partner Johan Kordel discusses the importance of Scandinavian biotch companies taking a strong international p ...

Evolving to the next phase of viral therapy development

2024.05.012024.05.13 / UK-based Theolytics is about to begin the first clinical trials for one of its cancer-fighting viruses. It’s a major step for any biotech company, often reached only after years of adjusting and read ...

Bringing everything together for an autoimmunity game changer

2023.09.202024.05.13 / At AbolerIS Pharma, it's all about creating balance. The Belgian/French biotech company is gearing up for clinical trials of a novel therapy for stabilizing chaotic immune systems. As CEO Ann Meulema ...

Reaching the next level of creating novel therapies for genetic diseases

2023.05.312024.05.13 / ARTHEx Biotech is entering a new phase in its development of breakthrough treatments for genetically-driven disorders. It’s set to begin the first clinical trials for one of its microRNA modulators a ...